Ilant has raised USD $15 million in Series A funding, taking total funding to more than USD $22 million.
Cornucopian Capital led the round, with participation from naturalX, Peakbridge, Semcap AI, Evidenced, Operator Partners, and existing backers Celtic, LifeX, and AlphaLab.
Founded by Elina Onitskansky, whose previous roles include positions at McKinsey and Molina Healthcare, Ilant works with employers and health plans on obesity treatment and related conditions. It combines clinician-led care with software and data analysis to tailor treatment over time.
The fundraising comes as employers and insurers face rising costs linked to obesity medicines, particularly GLP-1 drugs, while also facing pressure to expand access to treatment. Ilant's model is designed for that tension, offering programmes that combine behavioural therapy, medicines, and surgical options within a single service.
Early results from its member population show average weight loss of 15%. Members also recorded broader improvements in biomarkers and wellbeing, including an average of two additional mentally healthy days per month.
Its treatment approach draws on clinical, behavioural, and personal data to match members with different forms of care, including GLP-1 and non-GLP-1 medicines. The service is designed to adjust treatment pathways as patients respond over time rather than relying on a single intervention.
Employer demand
Ilant is already working with employers and healthcare partners as demand grows for obesity treatment models that link care delivery to outcomes and cost control. Interest has intensified as spending on weight-loss drugs has become one of the fastest-growing areas of healthcare budgets.
Kenneth L. Gardner, Director of Growth, Benefit Operations, described the appeal of the company's approach in employer settings.
"What stood out with Ilant was their precision-based, data-driven approach to obesity care, not a one-size-fits-all model centered on medication only," said Kenneth L. Gardner, Director of Growth, Benefit Operations. "Ilant conducted a detailed analysis of our population and identified the members most likely to benefit clinically and financially, giving us confidence in both improved outcomes and meaningful ROI. Just as importantly, the members consistently share positive feedback about the care, support, and personalized attention they receive from the Ilant team."
Ilant has also sought to address drug pricing more directly. In late 2025, it announced direct contracting and transparent pricing arrangements for obesity medicines through Lilly's Employer Connect programme, and it is also working with Novo Nordisk.
Those arrangements are intended to give employers more visibility into medicine costs and more flexibility in benefit design. The issue has become more pressing as use of GLP-1 therapies has risen sharply, lifting pharmacy bills for many large employers and health plans.
Cost pressure
Onitskansky said the market is grappling with a trade-off between broader access to treatment and mounting pharmaceutical costs.
"Employers and health plans are facing a real dilemma right now - they are faced with either expanding access and watching pharmaceutical costs rise dramatically, or restricting access and risking rising chronic disease and cost," said Elina Onitskansky, Founder and CEO, Ilant. "That's not a sustainable model. If we don't change how care is delivered, we're just paying more for the same broken system, and we risk a crisis where both chronic disease and costs are spiraling out of control. Ilant's model focuses on delivering real value with manageable treatment costs and clinically meaningful care that actually bends the cost curve."
Investors in the round said they see obesity and cardiometabolic care as a major opportunity for new healthcare services businesses, especially those that combine medical treatment with financial oversight for employers and insurers.
"We believe the next generation of category-defining companies will be those that deliver outcomes as a service, not just tools or access," said Aryeh Ganz, Founder and Managing Partner, Cornucopian Capital. "Ilant is applying that model to one of the most important and costly areas in healthcare. The company understands that the future of obesity and cardiometabolic care will not be defined by access to a single class of drugs, but by the ability to deliver the right care to the right patient at the right time. Their model aligns clinical rigor with economic value in a way that we believe will define this category over the next decade."